Immunodeficiency
Patients with Immunodeficiency are a high risk for complication for COVID-19, so balance for prompt face in face service and risk that those services pose need to be carefully evaluated. Those patients can be continued on IVIG per regular therapy, although the IVIG products are unlikely to cover for the current virus, given the still low prevalence in the general population. Consideration to switch to subcutaneous vs. IV formulation should be considered as well as at home vs. in hospital/office administration. Telehealth can be continued for those encounters that do not require in-person visit.6,7